dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
Published 6 years ago • 591 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:17
dr. oh on the safety profile of docetaxel in prostate cancer
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:47
dr. oh on remaining challenges with docetaxel in prostate cancer
-
1:10
dr. oh on the use of abiraterone and docetaxel in mcrpc
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
1:02
dr. oh discusses the role of chemotherapy in prostate cancer
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
1:33
dr. oh discusses the utility of cabazitaxel
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
0:20
copy of dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
1:15
dr. oh on the hormone-sensitive setting in prostate cancer
-
1:27
dr. zhang discusses the impact of the stampede trial in prostate cancer
-
1:11
dr. burgess on the synergy between abiraterone and adt in prostate cancer
-
1:24
dr. posadas on a phase ib study of abiraterone plus docetaxel for mcrpc
-
0:48
dr. kantoff on evolving role of docetaxel in prostate cancer treatment
-
0:41
dr. daniel petrylak discusses the future of abiraterone acetate